



### Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131

Zevra Therapeutics, Inc. (Zevra) provides the following information to Colorado prescribers pursuant to Colorado House Bill 19-1131 (HB 19-1131) in connection with prescription drug marketing activities.

The prices listed below are Wholesale Acquisition Costs (WAC) established and made available to the public by a third-party publisher.

Dosage Strength	OLPRUVA packet(s) in each envelope	Envelope NDC	Kit NCD	WAC/Unit
2 g	one 2 g packet (NDC 72542-002-01)	72542-200-02	72542-200-09	\$190.00
3 g	one 3 g packet (NDC 72542-003-01)	72542-300-02	72542-300-09	\$285.00
4 g	two 2 g packets	72542-400-02	72542-400-18	\$380.00
5 g	one 2 g packet and one 3 g packet	72542-500-02	72542-500-18	\$475.00
6 g	two 3 g packets	72542-600-02	72542-600-18	\$570.00
6.67 g	one 3 g packet and one 3.67 g packet (NDC 72542-367-01)	72542-667-02	72542-667-18	\$633.65

Generic Prescription Drugs from the same therapeutic class (as defined by HB 19-1131): Sodium phenylbutyrate powder and tablets.

The prices listed are WAC, which represent Zevra's published list prices for the product before any discount, rebate, or other price reduction. The WAC listed may differ significantly from actual prices paid by customers and consumers. In addition, a product's WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment, or the cost effectiveness of all the products listed.

The pricing information listed does not imply the safety or efficacy of the product. Please refer to the product's FDA-approved label and indication for further information at: [www.olpruva.com](http://www.olpruva.com).

Data as of: 06/30/2024